Tissue and organ engineering: Investor sentiments and analysis

Introduction: Regenerative medicine involves restoring natural function by replacing or regenerating human cells, tissues, or organs. Despite projections of significant market growth, venture capital (VC) investment in tissue and organ engineering has recently declined. Methods: We conducted a mixed-methods study using structured surveys and qualitative interviews. VC investors with experience in healthcare sectors (biotechnology, tissue engineering, and medical technology) were invited to complete a survey and participate in interviews. Results: We received 22 survey responses and conducted 9 interviews (April-May 2025). Prior exposure to regenerative medicine was significantly associated with future investment likelihood (p = 0.0464). Investment potential strongly correlated with assets under management (ρ = 0.67) and investment stage (ρ = 0.66). Among 20 respondents, clinical validation (n = 8) and adoption (n = 8) were most often cited as major investment drivers, followed by reimbursement and regulatory challenges. Interviews emphasized four factors shaping VC interest in tissue and organ engineering: prior investment experience, time horizon misalignment, clinical risk expectations, and market readiness. Discussion: Startups can improve appeal by targeting long-horizon investors, outlining clinical and regulatory pathways, and generating robust, comparative evidence to support value-based reimbursement.